Frost & Sullivan, in collaboration with Juoyuan Biology, has released the 'Global Market Research Report on Recombinant Type III Collagen'

● Anti-aging

Recombinant type III collagen inhibits matrix metalloproteinases (MMPs) from degrading dermal extracellular matrix (ECM).Recombinant type III collagen can increase the activity of superoxide dismutase and the scavenging rate of reactive oxygen species, inhibit the activation of mitogen-activated protein kinase (MAPK) signaling pathways, reduce the expression levels of MMP-1 and MMP-3, thereby reducing the degradation of dermal extracellular matrix and skin aging.

Recombinant type III collagen inhibits glycation reaction and damages dermal ECMRecombinant type III collagen can effectively reduce the content of malondialdehyde (MDA). MDA promotes glycation reactions, and by reducing its content, one can decrease the progression of glycation reactions; it can also significantly inhibit the synthesis of advanced glycation end products (AGEs), reducing glycation reactions that lead to aging skin.

●Regenerative repair

Recombinant type III collagen can regenerate dermal componentsRecombinant type III collagen can promote the increase in the three core components of the dermis—collagen fibers, elastic fibers, and collagen IV; it can also accelerate the migration and proliferation of keratinocytes, fibroblasts, etc., facilitating the rapid reconstruction of damaged areas.

Recombinant type III collagen regenerates a strong epidermal barrierRecombinant type III collagen aligns the arrangement of keratinocytes more neatly and tightly, improving the crystallization of the lipid structure between keratinocytes, enhancing the mechanical properties of the stratum corneum, and strengthening the barrier function of the stratum corneum. It can also upregulate skin barrier-related factors in keratinocytes, improving the resistance of the epidermal barrier.

The self-hydrating function of recombinant type III collagen is crucial for maintaining skin hydration and softness. By adding recombinant type III collagen to skincare products, while enhancing the natural moisturizing effects of the products, multiple skincare benefits can be achieved.

Recombinant Type III collagen (JYC301) can effectively exert its effects when added to skincare products such as aqueous solutions, serums, and creams, achieving improvements in wrinkle depth and size, skin elasticity, and pore volume.

By conducting comparative experiments between recombinant type III collagen and fish collagen peptides, bovine collagen peptides, etc., the cytotoxicity, cell viability, cell migration ability, transforming growth factor-β1 (TGF-β1) secretion, intracellular reactive oxygen species (ROS) levels, antioxidant enzyme activity, tyrosinase activity, etc., were detected.

The results show that recombinant type III collagen food (Pepwell™) has significant anti-aging, antioxidant, and whitening effects, and is safe for use in skin care and anti-aging foods.

The Report starts from multiple fields such as skincare products, medical aesthetics products, medical devices, food, scalp care, intimate care, oral care, and nasal care. It analyzes the efficacy trials of recombinant type III collagen. For more detailed content, please refer to the full report.

According to Frost & Sullivan's data analysis, from 2020 to 2023, the market scale of collagen raw materials in China increased from 1.63 billion yuan to 3.14 billion yuan, with a CAGR as high as 24.4%. It is estimated that by 2030, the market scale of collagen retail in China will reach 16.39 billion yuan.

In 2023, the market size of China's recombinant type III collagen raw material segment was RMB 810 million, accounting for 25.9% of the total collagen raw material market size; it is estimated that from 2023 to 2030, the market for recombinant type III collagen raw materials in China will grow rapidly at a compound annual growth rate (CAGR) of 43.5%. By 2030, the market size of recombinant type III collagen raw materials will reach RMB 1015 million, accounting for 62.0% of the total collagen retail market size.

According to Frost & Sullivan's data analysis, from 2020 to 2023, the global collagen raw material market size increased from $10.308 billion to $14.115 billion, with a CAGR of 11.0%. It will continue to grow at a CAGR of 15.3%. It is estimated that by 2030, the global collagen raw material market size will reach $38.148 billion.

From 2020 to 2023, the global market for recombinant type III collagen raw materials grew rapidly at a CAGR of up to 101.6% to reach $1.465 billion, accounting for 10.4% of the collagen raw materials market; it is estimated that by 2030, the global market for recombinant type III collagen raw materials will reach $15.86 billion, accounting for 41.6% of the overall collagen raw materials market.

According to data analysis by Frost & Sullivan, from 2020 to 2023, the retail market size of collagen in China increased from 20.47 billion yuan to 58.42 billion yuan, with a CAGR as high as 41.9%. It is estimated that by 2030, the retail market size of collagen in China will reach 269.5 billion yuan.

From 2020 to 2023, the retail market scale of recombinant type III collagen in China grew rapidly at a CAGR of 79.0%. In 2023, the retail market scale of recombinant type III collagen in China reached 205 billion yuan, accounting for 35.1% of the total collagen retail market scale; it is estimated that by 2030, the retail market scale of recombinant type III collagen will reach 138.37 billion yuan, accounting for 51.3% of the overall collagen retail market scale.

According to Frost & Sullivan's data analysis, from 2020 to 2023, the global collagen retail market size increased from $3,050.19 billion to $4,060.15 billion; it is estimated that by 2030, the global collagen retail market size will reach $783.713 billion.

From 2020 to 2023, the global retail market for recombinant type III collagen grew rapidly at a compound annual growth rate (CAGR) of 78.4%. In 2023, the global retail market for recombinant type III collagen was $30.638 billion; it is expected that by 2030, the retail market for recombinant collagen will reach $243.121 billion, accounting for 31.0% of the market size.

The Report makes judgments on the raw material and retail ends, as well as global and Chinese markets, for recombinant type III collagen based on different application scenarios. It fully demonstrates the market potential of recombinant type III collagen. For more detailed content, please refer to the full report.

Globally, the regulation of recombinant type III collagen is gradually moving towards standardization and systematization. Countries have introduced relevant policies to ensure its safety and effectiveness.

In our country, the supervision of recombinant type III collagen has entered a stage of improvement. It has not only been incorporated into the general regulatory framework for application fields but also specific regulatory measures have been formulated, effectively promoting product approval and standardized industry development. The state has established a series of industry standards and policy norms, which specify in detail the quality control requirements, testing indicators, and methods for recombinant collagen products, providing clear bases for production and supervision. Among them, two key industry standards, YY/T 1849-2022 "Recombinant Collagen" and YY/T 1888-2023 "Recombinant Humanized Collagen," have been released and implemented. These standards not only cover the quality control, testing indicators, and methods of recombinant collagen but also involve aspects such as the definition, classification, inspection, labeling, use, and safety of recombinant humanized collagen. They have a wide range of applications and reflect the comprehensiveness and systematicness of supervision.

The formulation and implementation of these standards are of great significance for regulating market order, guiding enterprise production activities, and ensuring the safety and effectiveness of end products. They not only provide clear guidance for the quality control of recombinant collagen in product raw materials but also encourage the research and development of new biomaterials, ultimately promoting the high-quality development of the industry.

The Report comprehensively sorts out the regulatory frameworks and core regulations for different products reconstituting type III collagen in countries and regions such as China, the United States, the European Union, and South Korea. For more information, please refer to the full report.

In recent years, China's collagen market has shown an unprecedented prosperity, especially in the field of medical aesthetics, where the launch and application of collagen products have attracted significant attention.

With the improvement of living standards and the transformation of social concepts, the recognition of medical aesthetics among the Chinese people has gradually risen, and the demand for collagen dressings used for postoperative repair has also continued to climb.

As of November 2024, there are nearly 400 types of collagen patches for medical use on the market in China, which fully reflects the urgent consumer demand for high-quality postoperative care products.

The Report showcases global and Chinese skincare products for the reconstruction of type III collagen, medical aesthetics products, food, scalp care, intimate care, oral care, nasal care, and other products. For more detailed content, please refer to the full report.

Juyuan Biotechnology is a high-tech enterprise focusing on the industrial design and application of biomimetic recombinant proteins. Since its establishment in 2015, the company has set up 3 marketing centers, 4 production bases, and 5 R&D centers globally. Juyuan Biotechnology has built a full industrial chain platform based on recombinant proteins, including gene design, strain construction, industrial design, ton-scale capacity expansion, downstream application R&D, downstream product safety and efficacy testing. With first-class biotechnological engineering technologies such as gene recombinantization, microbial fermentation, and protein separation and purification, it has achieved large-scale production of multiple functional proteins. Juyuan Biotechnology is one of the world's largest manufacturers of recombinant collagen, with world-leading unit expression levels of recombinant collagen.

As a comprehensive platform integrating R&D, production, and sales for the entire collagen industry chain, Juyuan Biotechnology has established a full range of product systems from raw materials to medical end products, functional skincare products, and functional foods. The company's products serve manufacturing enterprises, medical institutions, and end-users in multiple fields such as pharmaceuticals, medical aesthetics, cosmetics, biomaterials, food and health care globally, reaching more than 40 countries and regions including Europe, America, Asia, etc.

Deeply cultivating the underlying science of 'skin rejuvenation', Juyuan has taken the lead in revealing the core anti-aging value of type III collagen as the 'golden skeleton' of the skin, and established an 'all-category collagen development platform'. It has completed the matrix layout of recombinant collagen types III, I, V, 315, and 6D, pushing the industry from single-component competition into a new era of 'precision category-targeted repair'.